Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | BMC Cancer

Figure 5

From: Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

Figure 5

Apoptotic profiles of PLGem and GemPo on PANC1 Cells. The percentage of early and late apoptotic cells was quantified by the AnnexinV-propidium iodide flow cytometry method. PANC1 cells treated with free Gemcitabine (Gem) or Gemcitabine nanoformulations (PLGem or GemPo) for 2 days were subjected to FACS analysis. Cells were gated into four quadrants so as to measure viable cells: LL (lower left), early apoptosis: LR (lower right) and late apoptosis: UR (upper right). The percentage of cells per quadrant is depicted on the bottom and representative examples are shown on top.

Back to article page